Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Pharmacological management of obesity in patients with type 2 diabetes
Robin L Black1, Ashley M Higbea1, Courtney Duval1
1a School of Pharmacy , Texas Tech University Health Sciences Center , Dallas , TX , USA.
Introduction:
Obesity is a growing health concern worldwide. Multiple guidelines are available to clinicians to help guide treatment of obesity. Areas covered: In their 2016 update, the American Diabetes Association included recommendations for the use of pharmacological agents in the treatment of obesity in patients with concurrent diabetes. Five agents have been approved by the Food and Drug Administration and are recommended by guidelines for the long-term treatment of obesity: orlistat, lorcaserin, phentermine/topiramate ER, naltrexone/bupropion, and liraglutide. Expert commentary: This article summarizes the current evidence available on the use of these agents in patients with diabetes.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Drug Dosing: Obese Patients
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

